2026 MPS World Summit
May 26, 2026 – May 29, 2026
Washington, DC, USA
The mission of the HESI Cardiac Safety Committee is to improve public health by reducing unanticipated cardiovascular-related adverse effects from drugs or chemicals, and to develop innovative approaches to support early detection and prediction as well as improved understanding of cardiovascular toxicology and pathobiology.
This working group is dedicated to investigating preclinical cardiac biomarkers of hypercoagulability denoting increased thrombotic risk across diverse patient populations. In order to qualify novel and sensitive biomarker assays, we undertook preliminary pilot studies and have just completed a more comprehensive comparative study of distinct procoagulant and hypofibrinolytic stimuli. Data analyses and manuscript preparation are in progress, with submission in a peer reviewed journal planned for early 2025.
Leadership Team:
Florence Poitout, PhD (Charles River Laboratories)
Marjory Brooks, DVM (Cornell University)
The Cardiac Safety Steering Team established this subteam in early 2020 to develop and provide a structured resource for use when identifying compounds appropriate in a planned committee study. The database was published April 2024.
Additional compound suggestions will be reviewed annually.
HESI Staff:
Jennifer Pierson, MPH
This working group completed their partnership with the University of Surrey and Imperial College London on a mathematical model to predict blood pressure changes. The resulting manuscript was published in 2024. The new subteam exploring blood pressure measurements expanded to include a focus on developing nonclinical data in support of draft FDA guidance on pressor effects. This expansion resulted in new members joining the team. The interlaboratory study to assess changes in BP in the canine in vivo cardiovascular model is underway. This study is using telemetry recording methods to detect positive and negative effects as a result of drug exposures for compounds with known BP effects in the clinic.
Leadership Team:
Michael Pugsley, PhD (Cytokinetics)
HESI Staff:
Jennifer Pierson, MPH
Claire O’Brien, PhD
Alexandra Taraboletti, PhD
This working group is dedicated to investigating mechanisms of proarrhythmic risk. They continue to collaborate with the CiPA Initiative and ICH, and recently published its anticipated high throughput systems (HTS) ion channel work. A new subteam is scoping a conduction/ sodium channel paper to discuss the history and challenges surrounding this topic.
A 3-phased project was conducted by the HESI Pro-Arrhythmia Working Group starting with a detailed literature review and followed by a collaborative HESI-FDA database of 150 new drug candidates to evaluate how predictive nonclinical studies are to clinical outcomes.
Leadership Team:
Todd Bourcier, PhD (US Food and Drug Administration)
Jean-Pierre Valentin, PhD (UCB Biopharma)
HESI Staff:
Jennifer Pierson, MPH
Claire O’Brien, PhD
This group is working to understand and characterize use of stem cellāderived cardiomyocytes in cardiac safety assessments. An article that included best practices for use of stem cell cardiomyocytes in cardiac safety assessments was published in Regulatory Toxicology and Pharmacology. A new group is planning a study to explore in vitro assay ability to detect cardiotoxicity.
Leadership Team:
Ksenia Blinova, PhD (US Food and Drug Administration)
Godfrey Smith, PhD (University of Glasgow)
HESI Staff:
Jennifer Pierson, MPH
Alexandra Taraboletti, PhD
FDA U01 Validating Stem Cell Technology: HESI has been awarded a multi-year U01 grant from the US FDA on the āEvaluation of Integrated Human-Relevant Approaches to Identify Drug Induced Cardiovascular Liabilities.ā This grant supports HESI in funding and managing novel, in vitro experimental studies to develop targeted mechanistic data to inform drug safety assessment for key cardiac āfailure modes.ā
FDA BAA Ion Channel Patch Clamp Study: HESI received a Broad Agency Announcement (BAA) award from the US FDA to manage a multi-site study on manual and automated patch clamp platforms. The original study included 4 ionic currents (hERG, Nav1.5 peak, Nav1.5 late and Cav1.2) and 14 compounds and has been expanded to include a total of 28 compounds. The project aims to collect additional information on inter-laboratory variability as well as support the FDA in silico model. Learn more about the recommended ion channel protocols and in silico model here.
CiPA Project: The CiPA initiative begin following a workshop in July 2013 with the objective to improve the assessment proarrhythmic potential. HESI convened the CiPA Steering Team from 2013-2022 along with several of the work streams in support of novel data generation. The work has concluded and all data is publicly available on the CiPA website (https://cipaproject.org/) as well as additional information and links to ICH S7B/E14.

The HESI Cardiac Safety Committee seeks postdoctoral or early career researchers working in cardiovascular safety science or a related field for the Early Career Seminar Award Series. This award offers an opportunity to share your research, learn from and network with experts in the toxicology and safety pharmacology fields from academia, regulatory agencies and pharmaceutical companies.
Award: Selected candidates will receive a $500.00 USD award and be invited to present their research on a public webinar with HESI Cardiac Safety Committee scientists and other invited guests. Webinar dates will be scheduled with the awardees in Fall 2026.
Qualifications and Requirements: Eligible candidates must have a PhD or equivalent degree in biology or related field (cell biology, biochemistry, pathology, biomechanical engineering, or similar); have current post-doc position/appointment or consider themselves an early career scientist (~1-5 years post-academic training) and may not have previously received an award under this program.
Application: To apply, please send 1 PDF document with the following: 1) completed application form, 2) CV, and 3) one reference letter: cardiacsafety@hesiglobal.org.
Deadline for submission is 26 June 2026.
Past Award Winners
UCB
US Food and Drug Administration
May 26, 2026 – May 29, 2026
Washington, DC, USA
British Journal of Pharmacology, 2008
Knowledge of the cardiac safety of emerging new drugs is an important aspect of assuring the expeditious advancement of the best candidates targeted at unmet medical needs while also assuring the safety of clinical trial subjects or patients.
British Journal of Pharmacology, 2015
Evaluating whether a new medication prolongsĀ QTĀ intervals is a critical safety activity that is conducted in a sensitiveĀ animalĀ model during non-clinical drug development.
Toxicologic Pathology, 2025
In this new Toxicologic Pathology article from theĀ HESI Cardiac Safety Committeeās Biomarkers Working Group, Brooks et al. systematically evaluate a suite of hemostatic biomarkers in rat models of tissue factorādriven hypercoagulability (thromboplastin infusion) and impaired fibrinolysis (oral tranexamic acid).
Science Translational Medicine, 2016
Advances in cancer therapy has resulted in more cancer survivors, and now quality of life throughout treatment and surviving years is becoming a new focus for the scientific community. There are often unintended toxicities related to cancer therapies. HESI established the THRIVE program to address quality-of-life research.
Journal of Pharmacological and Toxicological Methods, 2019
Voltage-sensitive optical (VSO) sensors offer a minimally invasive method to study the time course of repolarization of the cardiac action potential (AP). This Comprehensive in vitro Proarrhythmia Assay (CiPA) cross-platform study investigates protocol design and measurement variability of VSO sensors for ...
Journal of Pharmacological and Toxicological Methods, 2020
Alterations in cardiac contractility can have significant clinical implications, highlighting the need for early detection of potential liabilities. Pre-clinical methods to assess contractility are typically invasive and their translation to human measures of cardiac function are not well defined. Clinically, cardiac ...
Click box below to view full poster
The Cardiac Safety Committee is part of the Center for Translational Sciences. This HESI Center serves as a focal point for staff to share strategic approaches, scientific developments, management best practices and innovations with other related HESI committees.
Other Committees in the Center for Translational Sciences are:
For questions about the Center contact:
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.